that it would have similar or enhanced efficacy compared with what we’d seen before, but it didn’t.”ADThe trial began on a hopeful note in 2016. That would have made production of the vaccine worthwhile for the two companies, Sanofi Pasteur and GSK, experts said. ADThe study was only the seventh large-scale human trial of a vaccine for HIV, which newly infected 1.7 million people worldwide in 2018, according to the Joint United Nations Program on HIV and AIDS. ADThat study is testing the vaccine on men who have sex with men and on transgender people in South America and Europe. The drugs have transformed HIV into a manageable virus by suppressing the level of the virus in the blood to undetectable levels in many people.

Source: Washington Post February 03, 2020 12:56 UTC